Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

• Published in: Journal of thoracic oncology Vol. 15; no. 5; pp. 816 - 826
• Main Authors: Gao, Shugeng, Li, Ning, Gao, Shunyu, Xue, Qi, Ying, Jianming, Wang, Shuhang, Tao, Xiuli, Zhao, Jun, Mao, Yousheng, Wang, Bing, Shao, Kang, Lei, Wendong, Wang, Dali, Lv, Fang, Zhao, Liang, Zhang, Fan, Zhao, Ziran, Su, Kai, Tan, Fengwei, Gao, Yibo, Sun, Nan, Wu, Dawei, Yu, Yue, Ling, Yun, Wang, Zhijie, Duan, Chunjian, Tang, Wei, Zhang, Lei, He, Shun, Wu, Ning, Wang, Jie, He, Jie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms - drug therapy; Neoadjuvant; Neoadjuvant Therapy; NSCLC; PD-1 inhibitor; PD-L1 expression; SUVmax; PD-L1 expression; SUVmax; Neoadjuvant; PD-1 inhibitor; NSCLC

Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is limited. This is a phase 1b study to evaluate the safety and outcome of PD-1 inhibitor in neoadjuvant setting. Treatment-naive patients...